Javascript must be enabled to continue!
SUNCT and SUNA, Distinct Disorders or Spectrum of a Single Clinical Entity? A Meta-analysis
View through CrossRef
ABSTRACT
This study aimed to evaluate and compare the relative frequencies of clinical features between SUNCT and SUNA. Recently, many researchers tried to investigate the relationship between them and disputed whether those two headache entities appear distinct or should be reconsidered as a single disorder. PubMed and Embase were searched for observational studies that reported clinical characteristics in adults diagnosed with SUNCT and SUNA, in accordance with ICHD-3 β and/or ICHD-3. To determine the pooled prevalence estimates of the clinical features, a random-effects meta-analysis was performed. The between-study heterogeneity was measured with I2
statistics. The study structure followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Risk of bias was assessed using Joanna Briggs Institute Checklist for Studies Reporting Prevalence Data. Of the initial 3834 records, 7 studies met eligibility criteria. The mean age of onset did not differ between the groups. A total of 22.9% (95% confidence interval [CI]: 9.5–45.6) subjects with SUNA present with conjunctival injection and 67.0% (95% CI: 29.4–90.9) with lacrimation. The next three most common cranial autonomic symptoms in both SUNCT and SUNA were rhinorrhea, nasal congestion, and ptosis. Restlessness and agitation were present in more than 40.0% of both entities. Single stab attacks were significantly more common in SUNCT (74.3%, 95% CI: 43.2–91.7) than in SUNA (21.8%, 95% CI: 11.3–37.8). In addition, subjects with SUNCT were more likely to benefit from topiramate (37.5%, 95% CI: 27.6–48.4) than SUNA patients (10.0%, 95% CI: 3.8–23.8). The results of our study showed that there were no major differences between SUNCT and SUNA and thus suggesting their common nature.
Ovid Technologies (Wolters Kluwer Health)
Title: SUNCT and SUNA, Distinct Disorders or Spectrum of a Single Clinical Entity? A Meta-analysis
Description:
ABSTRACT
This study aimed to evaluate and compare the relative frequencies of clinical features between SUNCT and SUNA.
Recently, many researchers tried to investigate the relationship between them and disputed whether those two headache entities appear distinct or should be reconsidered as a single disorder.
PubMed and Embase were searched for observational studies that reported clinical characteristics in adults diagnosed with SUNCT and SUNA, in accordance with ICHD-3 β and/or ICHD-3.
To determine the pooled prevalence estimates of the clinical features, a random-effects meta-analysis was performed.
The between-study heterogeneity was measured with I2
statistics.
The study structure followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Risk of bias was assessed using Joanna Briggs Institute Checklist for Studies Reporting Prevalence Data.
Of the initial 3834 records, 7 studies met eligibility criteria.
The mean age of onset did not differ between the groups.
A total of 22.
9% (95% confidence interval [CI]: 9.
5–45.
6) subjects with SUNA present with conjunctival injection and 67.
0% (95% CI: 29.
4–90.
9) with lacrimation.
The next three most common cranial autonomic symptoms in both SUNCT and SUNA were rhinorrhea, nasal congestion, and ptosis.
Restlessness and agitation were present in more than 40.
0% of both entities.
Single stab attacks were significantly more common in SUNCT (74.
3%, 95% CI: 43.
2–91.
7) than in SUNA (21.
8%, 95% CI: 11.
3–37.
8).
In addition, subjects with SUNCT were more likely to benefit from topiramate (37.
5%, 95% CI: 27.
6–48.
4) than SUNA patients (10.
0%, 95% CI: 3.
8–23.
8).
The results of our study showed that there were no major differences between SUNCT and SUNA and thus suggesting their common nature.
Related Results
SUNCT/SUNA in children and adolescents: Application of ICHD-3 criteria and treatment response: Case series of 13 SUNCT/SUNA pediatric cases
SUNCT/SUNA in children and adolescents: Application of ICHD-3 criteria and treatment response: Case series of 13 SUNCT/SUNA pediatric cases
Introduction
Trigeminal autonomic cephalalgias (TACs) are characterized by paroxysmal attacks of unilateral primary headaches associated with ipsilateral cranio...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Introduction Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the subcutaneous prophylactic treatment of hemophilia pati...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Introduction: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia associated antigen with chimeric antigen receptor T (CAR T) cells ...

